How
SAFEPATH Works

SAFEPATH integrates cheminformatics and bioinformatics to understand the mechanisms behind drug toxicity. In preclinical and clinical studies, safety assessments typically reveal what went wrong—such as liver failure or cardiac arrest—but fail to explain why these issues occurred or how they might be mitigated.

SAFEPATH combines advanced machine learning models with a multimodal data approach to enable a deep understanding of toxicity mechanisms, offering actionable insights to facilitate drug turnaround.

In this white paper, our Co-founder and Chief Data Science Officer Dr. Layla Hosseini-Gerami explains how our innovative platform works.

Submit
Thank you!
Download
Oops! Something went wrong while submitting the form.

Our Partners

Gaingels
Panacea Innovation
lqd
Blue Wire Capital
Modi Ventures
Montage Ventures
AIX Ventures
Genomics England
Milner Therapeutics Institute
Cancer Research UK
HESI Oasis
Lilly
AstraZeneca
Mass Challenge
British Toxicology Society
ELRIG UK
Royal Society of Chemistry
UKRI Innovate UK
Sanofi

Our Investors

Montage Ventures
AIX Ventures
Modi Ventures
Blue Wire Capital
Gaingels

Latest News

All
Blog
25.09.2026

What the ART preprint tells us about agents that read primary data

All
Research
17.09.2026

Divergent Mechanisms of Gefitinib Hepatotoxicity in Metabolically and Genetically Diverse Hepatocyte Models

All
Media
01.09.2026
Springer Nature

AI is transforming science. How do we ensure accountability?